SCHEMBL20128396

SCHEMBL20128396

COc1ccc2c(c1)sc1ncc(C(=O)O)n12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ TP53 P04637 2/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ MAPT P10636 3/20 0.49
▸ PTPN11 Q06124 1/20 0.48
▸ PARP15 Q460N3 2/20 0.48
▸ PARP10 Q53GL7 2/20 0.48
▸ TNKS2 Q9H2K2 2/20 0.48
▸ PARP2 Q9UGN5 2/20 0.48
▸ LMNA P02545 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ TSHR P16473 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ PDE11A Q9HCR9 2/20 0.44
▸ APP P05067 1/20 0.42
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7331482 0.84 IDO1 (0.56) ALDH1A1KDM4ETP53SMN1; SMN2MAPT
SCHEMBL20549125 0.84 ALDH1A1 (0.41) ALDH1A1KDM4ETP53SMN1; SMN2MAPT
SCHEMBL18747058 0.82 PARP10 (0.51) ALDH1A1KDM4ESMN1; SMN2MAPTPARP15
SCHEMBL20128397 0.81 TP53 (0.55) ALDH1A1KDM4ETP53SMN1; SMN2MAPT
SCHEMBL7331806 0.79 TP53 (0.52) ALDH1A1KDM4ETP53SMN1; SMN2MAPT
SCHEMBL7336368 0.79 TP53 (0.49) ALDH1A1KDM4ETP53SMN1; SMN2MAPT
SCHEMBL20549080 0.79 KDM4E (0.46) ALDH1A1KDM4EMAPTRAB9A
SCHEMBL20549093 0.77 MAPT (0.42) ALDH1A1KDM4ETP53SMN1; SMN2MAPT
SCHEMBL20549028 0.76 MAPT (0.49) ALDH1A1KDM4ETP53SMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL20549074 0.76 MAPT (0.41) ALDH1A1KDM4ETP53SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227361-B2 Fused imidazobenzothiazole compounds TORRENT PHARMACEUTICALS LIMITED (IN) 2019-03-12 — — US disclosed
US-20180127437-A1 NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127437-A1 NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS CYP3A5, CYP11B2, CYP3A4 ALDH1A1 2526/4885KDM4E 4213/4885TP53 2728/4885
US-10227361-B2 Fused imidazobenzothiazole compounds IPO4, CYP3A5, CYP3A4 ALDH1A1 2806/4885KDM4E 4381/4885TP53 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback